M. Wolf

2.0k total citations
72 papers, 1.3k citations indexed

About

M. Wolf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, M. Wolf has authored 72 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 24 papers in Epidemiology. Recurrent topics in M. Wolf's work include Lung Cancer Research Studies (34 papers), Neuroendocrine Tumor Research Advances (21 papers) and Lung Cancer Treatments and Mutations (18 papers). M. Wolf is often cited by papers focused on Lung Cancer Research Studies (34 papers), Neuroendocrine Tumor Research Advances (21 papers) and Lung Cancer Treatments and Mutations (18 papers). M. Wolf collaborates with scholars based in Germany, United States and France. M. Wolf's co-authors include K. Havemann, Rolf Holle, K. Hans, P. Drings, Gabriele Jaques, Manfred Heim, Maria Pritsch, Barbara Ritter, Maxim Kebenko and Gerold Bepler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

M. Wolf

70 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
M. Wolf 801 436 348 342 158 72 1.3k
Yifah Yaron 615 0.8× 336 0.8× 227 0.7× 382 1.1× 84 0.5× 17 1.4k
Satya Das 1.3k 1.6× 213 0.5× 489 1.4× 292 0.9× 259 1.6× 54 1.6k
Yuankai Shi 547 0.7× 276 0.6× 123 0.4× 395 1.2× 141 0.9× 101 997
Tommaso Martino De Pas 950 1.2× 307 0.7× 233 0.7× 943 2.8× 90 0.6× 45 1.5k
Natsuko Okita 855 1.1× 278 0.6× 236 0.7× 518 1.5× 105 0.7× 110 1.3k
Yasuo Ejima 379 0.5× 332 0.8× 210 0.6× 394 1.2× 90 0.6× 49 1.3k
Bradley G. Somer 808 1.0× 412 0.9× 149 0.4× 304 0.9× 123 0.8× 45 1.3k
Teresa Alonso‐Gordoa 619 0.8× 366 0.8× 333 1.0× 343 1.0× 95 0.6× 82 1.2k
A. Y. Chang 724 0.9× 230 0.5× 106 0.3× 494 1.4× 94 0.6× 40 1.3k

Countries citing papers authored by M. Wolf

Since Specialization
Citations

This map shows the geographic impact of M. Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Wolf more than expected).

Fields of papers citing papers by M. Wolf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Wolf. The network helps show where M. Wolf may publish in the future.

Co-authorship network of co-authors of M. Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of M. Wolf. A scholar is included among the top collaborators of M. Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Wolf. M. Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Faß, J., et al.. (2019). Multipel rezidivierendes retroperitoneales Liposarkom bei einem 66-jährigen Patienten. Der Internist. 61(2). 217–222. 1 indexed citations
2.
Thomas, Michael, Santiago Ponce-Aix, Alejandro Navarro, et al.. (2017). Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod. Annals of Oncology. 28. v539–v539. 5 indexed citations
3.
Schmid‐Bindert, Gerald, Walburga Engel-Riedel, Martin Reck, et al.. (2015). A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Lung Cancer. 90(3). 397–404. 9 indexed citations
4.
Braun, Ada, Walburga Engel-Riedel, Folker Schneller, et al.. (2015). Efficacy and Safety of Imprime Pgg, a Novel Innate Immune Modulator, in Combination with Bevacizumab (BEV), Carboplatin and Paclitaxel for the 1St-Line Treatment of Stage Iv Nsclc. Annals of Oncology. 26. i29–i29. 2 indexed citations
5.
Evans, Tracey L., Byoung Chul Cho, Katalin Udud, et al.. (2015). Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of Thoracic Oncology. 10(8). 1221–1228. 24 indexed citations
6.
Zurlo, Alfredo, Santiago Ponce Aix, Jorge Riera Knorrenschild, et al.. (2015). Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study. Annals of Oncology. 26. viii5–viii5. 1 indexed citations
7.
Marinis, Filippo de, Akin Atmaca, Marcello Tiseo, et al.. (2013). A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(8). 1091–1094. 41 indexed citations
8.
Fiedler, Walter, M. Wolf, Maxim Kebenko, et al.. (2012). A phase I study of  EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 2504–2504. 33 indexed citations
9.
Huber, Rudolf M., David F. Heigener, Cornelius F. Waller, et al.. (2012). Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial. Journal of Thoracic Oncology. 7(9). 1432–1439. 39 indexed citations
10.
11.
12.
Patel, Tejas, Liam Cornell, & M. Wolf. (2008). Renal metastases. Kidney International. 73(3). 370–370. 3 indexed citations
13.
Morschhauser, Franck, John F. Seymour, Hanneke C. Kluin‐Nelemans, et al.. (2007). A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Annals of Oncology. 19(2). 247–253. 88 indexed citations
14.
Seifart, Ulf, Thomas Fink, Carmen Schade‐Brittinger, et al.. (2006). Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Annals of Oncology. 18(1). 104–109. 2 indexed citations
15.
Seifart, Ulf, Katrin Jensen, M. Schröder, et al.. (2005). Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer. 48(3). 415–422. 15 indexed citations
16.
Wolf, M., et al.. (2004). First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer. 45. S223–S234. 14 indexed citations
17.
Weide, Rudolf, M. Wolf, Ulrich Kaiser, et al.. (1997). Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. British Journal of Haematology. 96(1). 117–123. 26 indexed citations
18.
Carney, Desmond N., Jonas Bergh, Austin Doyle, et al.. (1989). Biological response modifiers in the management of small cell lung cancer: a consensus report. Lung Cancer. 5(4-6). 143–145. 1 indexed citations
19.
Havemann, K., M. Wolf, Rolf Holle, et al.. (1987). Alternating versus sequential chemotherapy in small cell lung cancer. A randomized german multicenter trial. Cancer. 59(6). 1072–1082. 46 indexed citations
20.
Wolf, M., K. Havemann, Rolf Holle, et al.. (1987). Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.. Journal of Clinical Oncology. 5(12). 1880–1889. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yifah Yaron Breakdown of academic impact, for papers by Satya Das Breakdown of academic impact, for papers by Yuankai Shi Breakdown of academic impact, for papers by Tommaso Martino De Pas Breakdown of academic impact, for papers by Natsuko Okita Breakdown of academic impact, for papers by Yasuo Ejima Breakdown of academic impact, for papers by Bradley G. Somer Breakdown of academic impact, for papers by Teresa Alonso‐Gordoa Breakdown of academic impact, for papers by A. Y. Chang
Rankless by CCL
2026